1.
|
Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C05004, NCT00257114
|
|
2.
|
Phase: Phase IV Type: Natural history/Epidemiology, Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR003469, 26866138MMY4001, NCT00440765
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: TaCyDexVMP7, NCT00652041
|
|
4.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR012958, bortezomib PMS, NCT01005628
|
|
5.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR015814, 26866138MMY4039, BORKOR5021, NCT01030302
|
|
6.
|
Phase: Phase IV Type: Natural history/Epidemiology Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR016750, BOR-KOR-5022, NCT01060202
|
|
7.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA200-003, KAG-302, NCT00514371
|
|
8.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: CR005242, NCT00833560
|
|
9.
|
Phase: Phase III, Phase II Type: Diagnostic, Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: R08096M, 2008-003936-38, 26866138MMY2063, NCT00861250
|
|
10.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MILLENNIUM-M34101-040, FHCRC-1747.00, NCI-G02-2128, NCT00049478
|
|
11.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MILLENNIUM-M34101-039, FHCRC-1746.00, NCI-G02-2130, NCT00048230
|
|
12.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2003-35, NCT00093028
|
|
13.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR004117, DOXILMMY3001, 2004-001842-34, NCT00103506
|
|
14.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: UARK 2005-01, NCT00111748
|
|
15.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EudraCT: 2005-001628-35, EBMT-CLWP: 42206611, NCT00256776
|
|
16.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: BRD 04/11-J, NCT00200681
|
|
17.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 26866138-MMY-3002, UCLA-0409110-01, JJPRD-26866138-MMY-3002, NCT00111319
|
|
18.
|
Phase: Phase III Type: Treatment Status: Closed Age: 61 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: CR006127, 26866138MMY3013, NCT00416208
|
|
19.
|
Phase: Phase III Type: Treatment Status: Closed Age: 0 to 60 Sponsor: Pharmaceutical / Industry Protocol IDs: CR006124, NCT00416273
|
|
20.
|
Phase: Phase III Type: Treatment Status: Completed Age: Over 18 Sponsor: Pharmaceutical / Industry Protocol IDs: 26866138-LYM-3001, NCT00312845
|
|
21.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: NMSG 15/05, EudraCT No: 2005-002756-18, NCT00417911
|
|
22.
|
Phase: Phase III Type: Treatment Status: Completed Age: 66 and over Sponsor: Other Protocol IDs: 2005-001111-21, NCT00443235
|
|
23.
|
Phase: Phase III Type: Treatment Status: Completed Age: 65 and under Sponsor: Other Protocol IDs: 2005-001110-41, NCT00461747
|
|
24.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C05009, NCT00507416
|
|
25.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2009-00521, U10CA021115, CDR0000561758, E1A05, ECOG-E1A05, NCT00522392
|